196 related articles for article (PubMed ID: 16628770)
1. Trial shows HSV-2 suppression can reduce HIV shedding.
IAVI Rep; 2006; 10(1):20. PubMed ID: 16628770
[No Abstract] [Full Text] [Related]
2. HSV-2 suppression reduces HIV and HSV shedding.
Collins S
GMHC Treat Issues; 2005 Dec; 19(12):11. PubMed ID: 16909510
[No Abstract] [Full Text] [Related]
3. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
4. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
[TBL] [Abstract][Full Text] [Related]
5. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
6. An addition to the effect of treating co-infections on HIV-1 viral load.
Modjarrad K; Vermund SH
Lancet Infect Dis; 2011 Feb; 11(2):81. PubMed ID: 21272789
[No Abstract] [Full Text] [Related]
7. Recent developments in the management of herpes simplex virus infection in HIV-infected persons.
Bartlett JG
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S237-9. PubMed ID: 15494894
[No Abstract] [Full Text] [Related]
8. HSV shedding.
Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
[TBL] [Abstract][Full Text] [Related]
9. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
10. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
11. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
[TBL] [Abstract][Full Text] [Related]
12. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
13. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
[TBL] [Abstract][Full Text] [Related]
14. Time to refocus on HSV interventions for HIV prevention?
Tanton C; Abu-Raddad LJ; Weiss HA
J Infect Dis; 2011 Dec; 204(12):1822-6. PubMed ID: 21998480
[No Abstract] [Full Text] [Related]
15. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
17. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
[TBL] [Abstract][Full Text] [Related]
18. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.
LeGoff J; Weiss HA; Gresenguet G; Nzambi K; Frost E; Hayes RJ; Mabey DC; Malkin JE; Mayaud P; Belec L
AIDS; 2007 Jul; 21(12):1569-78. PubMed ID: 17630552
[TBL] [Abstract][Full Text] [Related]
19. Synergistic copathogens--HIV-1 and HSV-2.
Corey L
N Engl J Med; 2007 Feb; 356(8):854-6. PubMed ID: 17314346
[No Abstract] [Full Text] [Related]
20. Health care seeking among men with genital ulcer disease in South Africa: correlates and relationship to human immunodeficiency virus-1 and herpes simplex virus type 2 detection and shedding.
Leichliter JS; Lewis DA; Sternberg M; Habel MA; Paz-Bailey G
Sex Transm Dis; 2011 Sep; 38(9):865-70. PubMed ID: 21844743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
